InnoCare announces first subject dosed in clinical trial of TL1A/IL-23p19 bispecific antibody ICP-B161 in China.
🇨🇳 China · Map
InnoCare announces first subject dosed in clinical trial of TL1A/IL-23p19 bispecific antibody ICP-B161 in China.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in